TJP1 and cancer: As in many other cancers, HCC progression is characterized by EMT with loss of epithelial markers (e.g., E-cadherin, ZO-1, Cytokeratin) and gain of mesenchymal markers (e.g., Vimentin, TWIST1, ZEB1, CD44, SNAI1, SNAI2)38.